Yesterday, July 14, 2016, 30 U.S. common stocks issued filings of shares being bought or sold by insiders. The transactions ranged in value from $1,036.95 to $3,821,860.00.

Highlighted Stocks Traded by Insiders:

MACOM Technology Solutions Holdings (MTSI) - FREE Research Report

Virk Preetinder S., who is SVP and GM, Carrier Networks at MACOM Technology Solutions Holdings, sold 3,177 shares at $35.00 on July 14, 2016. Following this transaction, the SVP and GM, Carrier Networks owned 43,946 shares meaning that the stake was reduced by 6.74% with the 3,177-share transaction.

The shares most recently traded at $35.34, up $0.34, or 0.96% since the insider transaction. Historical insider transactions for MACOM Technology Solutions Holdings go as follows:

  • 4-Week # shares sold: 2,000
  • 12-Week # shares sold: 45,391
  • 24-Week # shares sold: 59,338

The average volume for MACOM Technology Solutions Holdings has been 647,500 shares per day over the past 30 days. MACOM Technology Solutions Holdings has a market cap of $1.9 billion and is part of the technology sector and electronics industry. Shares are down 13.79% year-to-date as of the close of trading on Thursday.

M/A-COM Technology Solutions Holdings, Inc., together with its subsidiaries, designs, develops, manufactures, and markets analog RF, microwave, millimeter wave, and photonic semiconductor products in the United States, China, Taiwan, Japan, and internationally. Currently, there are 7 analysts who rate MACOM Technology Solutions Holdings a buy, no analysts rate it a sell, and 1 rates it a hold.

Exclusive Offer: Get the latest Stock Analysis on MTSI - FREE

TheStreet Quant Ratings

rates MACOM Technology Solutions Holdings as a

hold

. The company's strengths can be seen in multiple areas, such as its robust revenue growth, good cash flow from operations and expanding profit margins. However, as a counter to these strengths, we also find weaknesses including disappointing return on equity, a generally disappointing performance in the stock itself and unimpressive growth in net income. Get the full

MACOM Technology Solutions Holdings Ratings Report

from

TheStreet Quant Ratings

now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

DexCom (DXCM) - FREE Research Report

Sayer Kevin R, who is President & CEO at DexCom, sold 7,000 shares at $79.92 on July 14, 2016. Following this transaction, the President & CEO owned 342,227 shares meaning that the stake was reduced by 2% with the 7,000-share transaction.

The shares most recently traded at $77.48, down $2.44, or 3.15% since the insider transaction. Historical insider transactions for DexCom go as follows:

  • 4-Week # shares sold: 48,860
  • 12-Week # shares sold: 88,690
  • 24-Week # shares sold: 130,753

The average volume for DexCom has been 903,300 shares per day over the past 30 days. DexCom has a market cap of $6.6 billion and is part of the health care sector and health services industry. Shares are down 4.63% year-to-date as of the close of trading on Thursday.

DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring systems in the United States and internationally. Currently, there are 11 analysts who rate DexCom a buy, 1 analyst rates it a sell, and 2 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on DXCM - FREE

TheStreet Quant Ratings

rates DexCom as a

sell

. The company's weaknesses can be seen in multiple areas, such as its deteriorating net income, disappointing return on equity, weak operating cash flow and feeble growth in its earnings per share. Get the full

DexCom Ratings Report

from

TheStreet Quant Ratings

now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

ResMed (RMD) - FREE Research Report

Hollingshead James, who is President, Americas at ResMed, sold 2,753 shares at $65.02 on July 14, 2016. Following this transaction, the President, Americas owned 40,669 shares meaning that the stake was reduced by 6.34% with the 2,753-share transaction.

The shares most recently traded at $64.82, down $0.20, or 0.3% since the insider transaction. Historical insider transactions for ResMed go as follows:

  • 4-Week # shares sold: 4,458
  • 12-Week # shares sold: 4,458
  • 24-Week # shares sold: 40,904

The average volume for ResMed has been 869,300 shares per day over the past 30 days. ResMed has a market cap of $9.0 billion and is part of the health care sector and health services industry. Shares are up 21.25% year-to-date as of the close of trading on Thursday.

ResMed Inc. develops, manufactures, distributes, and markets medical equipment for the diagnosis, treatment, and management of respiratory disorders with a focus on sleep-disordered breathing (SDB). The stock currently has a dividend yield of 1.86%. The company has a P/E ratio of 26.4. Currently, there are 2 analysts who rate ResMed a buy, 3 analysts rate it a sell, and 4 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on RMD - FREE

TheStreet Quant Ratings

rates ResMed as a

buy

. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures, good cash flow from operations, solid stock price performance and expanding profit margins. We feel its strengths outweigh the fact that the company has had sub par growth in net income. Get the full

ResMed Ratings Report

from

TheStreet Quant Ratings

now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.